权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of SuPAR in the Intersection between Cardiovascular and Kidney Disease

SuPAR 在心血管疾病和肾脏疾病交叉点中的作用

基本信息

批准号：
10029263
负责人：
Salim Hayek
金额：
$ 53.64万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10029263
关键词：
Address Arterial Fatty Streak Atherosclerosis Biological Markers Blood Circulation Bone Marrow Brain natriuretic peptide C-reactive protein Cardiovascular Diseases Cardiovascular system Cause of Death Chronic Chronic Kidney Failure Data Data Set Development Diffuse Discrimination Disease Disease Outcome Endothelium Enrollment Environmental Exposure Epidemiology Etiology Experimental Models Foundations Functional disorder Funding Genes Genetic Genetic Determinism Glycoproteins Goals Inflammation Inflammatory Injections Injury Injury to Kidney Innate Immune System Kidney Kidney Diseases Knowledge Link Measurement Measures Membrane Meta-Analysis Multi-Ethnic Study of Atherosclerosis Myeloid Cells Outcome PLAU gene PLAUR gene Participant Pathogenicity Pathway interactions Patients Pharmacology Placebos Plasminogen Population Preventive Intervention Process Prospective Studies Prospective cohort Randomized Recombinant Proteins Renal function Research Risk Risk Factors Role Sampling Science Secure Signaling Molecule Surface Testing Therapeutic Intervention Therapeutic Studies Troponin I Tubular formation United States United States National Institutes of Health Urokinase Urokinase Plasminogen Activator Receptor Virulence Factors Work arterial stiffness base biobank cardiovascular disorder risk cardiovascular risk factor clinical practice cohort coronary artery calcium coronary calcium scoring cytokine data warehouse design disorder risk experience experimental study follow-up genetic variant genome wide association study healthy volunteer high risk individualized medicine insight kidney dysfunction modifiable risk multidisciplinary novel overexpression prevent randomized trial receptor response rosuvastatin therapeutic target volunteer

项目摘要

Project Summary People with chronic kidney disease (CKD), who represent over 15% of the population of the United States, suffer a disproportionately high burden of cardiovascular disease (CVD) for reasons that are poorly understood. Inflammation represents the major pathophysiologic process common to both atherosclerosis and CKD. Recently, a novel pathway of inflammation was uncovered linking both CVD and CKD to bone marrow myeloid cells which produce a circulating signaling molecule: soluble urokinase plasminogen activator receptor (suPAR). SuPAR is released by immature myeloid cells in response to environmental exposures and CVD risk factors. In circulation, suPAR alters glomerular and tubular function, with chronic exposure leading to progressive kidney dysfunction. Pharmacologic inhibition of suPAR in experimental models prevented kidney injury. SuPAR levels also predict adverse cardiovascular outcomes independently of kidney function, and outperform well-established markers of CVD risk, such as coronary calcium, C-reactive protein, high sensitivity troponin I and B-type natriuretic peptide. These compelling data reveal the potential for suPAR not only as an excellent biomarker of risk, but also as a promising therapeutic target. The role of suPAR in CVD is however poorly understood. The overall goal of this proposal is to elucidate suPAR’s potential causal role in the progression of atherosclerosis and its link to decline in kidney function through epidemiologic insights. We will achieve this goal by leveraging three of the most significant contributions to cardiovascular science: the landmark Multi-Ethnic Study of Atherosclerosis (MESA); an NIH-funded prospective cohort in which enrollees underwent serial measurements of subclinical markers of atherosclerosis, the JUPITER trial, in which participants with high C-reactive protein levels were randomized to statin or placebo, and the UK Biobank, a data repository of over 500,000 volunteers. SuPAR levels will be measured in 5,620 participants of MESA to determine whether levels correlate with early markers of CVD and predicts their progression independently of a decline in kidney function. To assess potential causality, a gene-wide association study of suPAR levels in MESA, followed by a Mendelian randomization analysis in the UK Biobank dataset will connect genetic determinants of suPAR levels to CVD and CKD. Lastly, to establish whether suPAR is a modifiable risk factor for CVD, levels will be measured serially in participants of the JUPITER trial randomized to rosuvastatin (n=200) or placebo (n=200), and the change in suPAR will be compared between groups. Whether the benefits of statins are dependent on suPAR levels will be assessed in the MESA cohort by comparing the survival of participants started on statins across suPAR quartiles, and determining whether suPAR is a modifier of the association between statins and outcomes. The proposed research has the potential to address the unmet need of close to 50 million people with CKD in the United States alone, identifying sorely needed therapeutic targets and management strategies in a field that has long been stagnant.

项目总结